FOXO Technologies 3Q 2026: Revenue $7M — 10-Q Summary

FOXO Technologies reported 3Q 2026 revenue of $7M, up 97.38% YoY, with earnings shifting from a loss to income. Growth was driven by higher RCHI revenue, including Medicare adjustments and rate changes. The Life Science Services segment saw revenue increase to $406,953. The Grifols acquisition remains pending regulatory approvals and financing.

Original reporting
Published Nov 16, 2026, 5:51 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 6:10 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
FOXO Technologies 3Q 2026: Revenue $7M — 10-Q Summary — source image
Decision brief

The 30-second read

$FOXOBullishMed
01

Why it matters

Traders can use the disclosed drivers of revenue and operating income to reassess near-term earnings power, while monitoring the unresolved Grifols acquisition as a potential catalyst or drag depending on regulatory and financing progress.

02

Market read

A quarterly filing summary with concrete financial direction and identifiable drivers, plus a pending M&A-related overhang.

03

What to watch

The labs segment ceased R&D under a technology license agreement, and the Grifols acquisition remains pending, both of which could affect forward earnings quality and timing.

Relevance 6/10Novelty 6/10Timing: latest 10-Q summary, available after-hours/late day

Background

The piece summarizes FOXO Technologies’ 3Q 2026 Form 10-Q, including segment performance and a pending acquisition update.

Company-level read

Ticker impact

$FOXOBullishMedium confidence
Context

FOXO’s 3Q 2026 10-Q summary reports revenue up 97.38% YoY and improved earnings, driven by higher RCHI Medicare-related revenue and swing-bed volume.

Expected impact

Likely upward bias as investors price in stronger Medicare-linked revenue, tempered by risk that the Grifols acquisition timing slips.

Evidence & confidence

The article provides specific directional financial improvements and identifies key drivers (RCHI Medicare adjustments, rate changes, swing-bed volume), while also noting the Grifols acquisition has not closed and regulatory/financing items remain outstanding.

Market effects

Highlights how Medicare cost-report adjustments, rate changes, and swing-bed volume can materially swing healthcare services revenue and margins.

No specific regional impact described.

Primarily US Medicare reimbursement dynamics; limited global spillover.

Counterpoint

Revenue growth may be partly driven by Medicare cost-report adjustments and rate changes, which can be non-recurring or subject to future reconciliation.

Key entities

  • FOXO Technologies Inc.

    Subject of the 10-Q summary, reporting sharp YoY revenue growth and improved earnings, with segment and acquisition updates.

  • Grifols

    Counterparty in a proposed four-center acquisition that has not closed due to regulatory authorizations and financing remaining outstanding.

Related articles

$JDMed

What JD.com (JD) Said on Its Q3 Earnings Call

JD.com reported Q3 earnings, noting a 50% YoY reduction in food delivery losses and 16.1% revenue growth in JD Logistics. AI investments and international expansion were highlighted, with plans to reduce food delivery investments in 2027. JD Retail aims for high single-digit margins long-term. The company closed its CECONOMY acquisition and saw Joybuy revenue grow 35% QoQ. Annual active users exceeded 750 million, with strong free cash flow growth.

$ONEWMed

OneWater Marine Q4 Earnings Call Highlights

OneWater Marine reported Q4 results with $54M in cash, $58M in liquidity, and debt reduced to $342M. Net leverage improved to 3.8x EBITDA. The company projected 2027 revenue of $1.78B-$1.88B and adjusted EBITDA of $80M-$95M. Fort Lauderdale Boat Show sales were slightly higher in units but lower in dollars. Pre-owned boat sourcing remains challenging, supporting price stability.

$SMWBMed

What Similarweb (SMWB) Said on Its Q3 Earnings Call

Similarweb (SMWB) reported Q3 earnings, noting a 6% YoY increase in customers spending over $100k ARR and a 27% rise in their average account value. The company raised its 2026 revenue forecast to $318M-$320M and expects Q4 revenue of $83.9M-$85.9M. Similarweb is seeing growth in AI-related products and partnerships, like a multiyear deal with NIQ. No single customer represents over 10% of revenue, and the company has multiple large, multiyear engagements.

$NXNTMedAI 8/10

Nexscient Reports Third Quarter 2026 Results

Nexscient, Inc. (NXNT) filed an SEC Form 8-K — Regulation FD Disclosure. EXHIBIT 99.1 Nexscient Reports Third Quarter 2026 Results; Revenue Rises Sequentially as Gross Margin Expands to Over 40% Nine-Month Pro Forma Revenue of $2.96 Million, Up 65% Year over Year LOS ANGELES / NOVEMBER 17, 2026 / ACCESSWIRE — Nexscient, Inc. (OTCQB: NXNT) (“Nexscient”